Filtered By:
Source: Diabetologia
Condition: Heart Failure
Countries: Australia Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Conclusions/interpretationAt current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes.Graphical abstract
Source: Diabetologia - February 22, 2023 Category: Endocrinology Source Type: research
